Retatrutide (LY3437943) is Eli Lilly's triple agonist — same playbook as tirzepatide but adding a third receptor (glucagon) to the existing GLP-1 + GIP stack. It's currently in Phase 3 (the TRIUMPH series), and the Phase 2 data was striking enough to make 'retatrutide' a household name in the GLP-1-watcher community well before any approval. Structurally similar to tirzepatide (39-amino acid pepti

How does Retatrutide work?

On top of the GIP + GLP-1 synergy you get with tirzepatide, glucagon receptor activation drives energy expenditure and fat oxidation directly — it's the same mechanism that gives natural glucagon its fat-burning effects (increased hepatic glucose output, increased fatty acid oxidation). The 'triple-hit' approach is supposed to attack obesity from three angles at once: appetite suppression (GLP-1),

What are typical research doses for Retatrutide?

Trial protocols start at 0.5 mg weekly and titrate up through 1.0 → 2.0 → 4.0 → 8.0 → 12.0 mg every 4 weeks. The slow titration matters more than usual here because the glucagon component can drive heart rate increases and GI side effects more aggressively than pure GLP-1. The final approved dose schedule will depend on Phase 3 data — there's a real possibility the labeled max ends up lower than t

What are the main safety considerations?

So far retatrutide's side effect profile mirrors GLP-1/GIP drugs — GI-dominated, with Phase 2 reporting 39% nausea, 24% diarrhea, 21% vomiting at the highest doses. The glucagon-related concerns are mostly theoretical at this point: dose-dependent heart rate increases of 5-7 bpm have been documented, and high-dose diabetic patients need close glucose monitoring. Long-term safety data is still bein

Retatrutide Research

Q: Is Retatrutide FDA-approved?

FDA approval status depends on the specific compound. Most research peptides are not FDA-approved for human use and are sold as research chemicals for laboratory use only. Some peptides in the broader landscape (semaglutide, tirzepatide, tesamorelin, setmelanotide) are FDA-approved.

Compliance & Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.

IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.

Reviewed by: WolveStack Research Team

Last reviewed: 2026-04-28

Educational research only. The compounds discussed here are not approved by the FDA, EMA, MHRA, TGA, or Health Canada for human therapeutic use. They are research chemicals. Nothing on this page is medical advice. You must be 18+. Consult a licensed healthcare professional before acting on anything you read. Full disclaimer →

Editorial policy

Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.

Medical Disclaimer

For informational and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed healthcare professional. See full disclaimer.

Comprehensive guide to retatrutide research: research, benefits, dosing, safety, and practical information for optimal use.

What Is Retatrutide?

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist peptide developed for weight loss and metabolic health. It represents the next generation of incretin-based therapeutics, offering broader mechanism of action than dual GLP-1/GIP agonists like tirzepatide.

Mechanism of Action

Retatrutide activates three receptor pathways simultaneously: GLP-1 receptors (glucose control, satiety), GIP receptors (nutrient sensing, lipid metabolism), and glucagon receptors (metabolic rate, fat mobilization). This tripartite mechanism produces additive effects on weight loss, glycemic control, and metabolic rate.

Efficacy and Clinical Evidence

Phase 2 clinical trials demonstrate superior weight loss with retatrutide compared to semaglutide and tirzepatide at equivalent dose levels. Average weight loss ranges 15-24% of baseline body weight over 48 weeks, compared to 15-20% with tirzepatide and 12-18% with semaglutide.

Dosing and Administration

Standard dosing follows a titration protocol starting at low doses and escalating to maintenance over 4-6 weeks. Most users tolerate maintenance doses of 7.5-15 mg weekly via subcutaneous injection. Doses are administered once weekly, typically on the same day each week.

Side Effects and Safety

Common side effects mirror GLP-1 agonists: nausea (20-30%), vomiting (5-10%), diarrhea (15-20%), and constipation (10-15%). Serious adverse events are rare. Contraindications include personal/family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2.

Practical Application and Results

Users typically experience rapid appetite suppression, reduced food cravings, and effortless weight loss. Most report clinically significant weight reduction within 4-8 weeks. Metabolic improvements (insulin sensitivity, blood pressure, lipid profiles) accompany weight loss.

Comparison With Other Agents

Retatrutide offers superior efficacy to semaglutide and potentially equivalent or superior efficacy to tirzepatide, with emerging data suggesting better metabolic benefits due to glucagon receptor activation. Cost and availability currently limit widespread adoption.

Long-Term Considerations

Long-term safety data is still accumulating. Most weight loss occurs in the first 12-24 weeks; plateau occurs thereafter. Discontinuation typically results in weight regain, requiring chronic maintenance therapy for sustained benefits.

Combination Strategies

Retatrutide combines effectively with lifestyle modifications (diet, exercise, sleep optimization). Some users combine with other metabolic agents (metformin, SGLT2 inhibitors) though interactions require medical supervision.

2026 Phase 3 Update: TRIUMPH-4 and TRANSCEND-T2D-1

Two major Phase 3 readouts in 2026 substantially advance the retatrutide evidence base.

TRIUMPH-4: Knee Osteoarthritis + Obesity

TRIUMPH-4 was a randomized, placebo-controlled Phase 3 trial in adults with obesity and knee osteoarthritis. The 12 mg weekly dose group lost an average of 28.7% body weight (approximately 32.3 kg / 71 lbs) and showed substantial reduction in knee OA pain measured by validated WOMAC scores. The pain improvement exceeded what weight loss alone would predict, making TRIUMPH-4 the first Phase 3 trial to document direct musculoskeletal benefit from a GLP-1-class drug. Mechanism hypotheses center on anti-inflammatory effects of the triple GLP-1/GIP/glucagon agonism on joint tissue. Full breakdown in our dedicated retatrutide for osteoarthritis article.

TRANSCEND-T2D-1: Type 2 Diabetes

TRANSCEND-T2D-1 reported retatrutide as a type 2 diabetes therapy, with HbA1c reductions and weight loss exceeding tirzepatide head-to-head comparison data from the SURPASS program. Specific magnitudes are pending full publication; topline results indicated retatrutide as a leading candidate for the next-generation diabetes-plus-weight-loss combination indication.

New Safety Signal: Dysesthesia

Across the Phase 3 program, retatrutide produced a clear dose-dependent dysesthesia signal — abnormal sensation (typically tingling, burning, prickling in extremities) in 8.8 to 20.9% of dose-group patients versus 0.7% on placebo. This is one of the distinguishing safety findings between retatrutide and older GLP-1 class drugs. Most cases were mild to moderate; severe cases were uncommon but documented. See our dysesthesia article for full discussion.

Implications

The 2026 Phase 3 data positions retatrutide as the leading candidate for FDA approval in the GLP-1 class with the strongest weight loss numbers, demonstrated direct OA pain benefit, and a meaningfully different safety profile than older drugs (better in some ways, worse for the dysesthesia signal). Approval pathway for the weight-loss indication is widely expected within 12-24 months. OA-specific labeling is uncertain.

Frequently Asked Questions

Is retatrutide FDA approved?

Retatrutide is currently in clinical development and not yet FDA approved. Availability is limited to clinical trials or research peptide suppliers for off-label use.

How does retatrutide compare to semaglutide or tirzepatide?

Retatrutide shows superior weight loss compared to semaglutide and potentially superior efficacy to tirzepatide due to triple receptor activation. Exact comparison data is still emerging.

What are realistic weight loss expectations?

Average weight loss is 15-24% of baseline body weight over 48 weeks. Individual results vary based on baseline weight, metabolism, diet adherence, and activity level.

Are there serious side effects to be aware of?

Serious adverse events are rare in clinical trials. The main safety concern is medullary thyroid carcinoma risk (theoretical, based on animal studies) in genetically susceptible individuals.

Can you combine retatrutide with other weight loss medications?

Combining with other GLP-1 agonists is not recommended due to redundant mechanisms. Combination with other classes (orlistat, topiramate, phentermine) may be possible but requires medical supervision.

What happens when you stop retatrutide?

Weight loss is typically sustained for 6-12 months after discontinuation, then gradual weight regain occurs. Many patients require chronic maintenance therapy for sustained benefits.

Particle Peptides

Pure research peptides with HPLC verification and competitive pricing.

Shop Particle

Limitless Life

Premium research peptides with full documentation and support.

Shop Limitless